Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Smita De

Urology Nashville, TN Medical Doctor

NPI 1295051415 CMS profile 1386099

3601 The Vanderbilt Clinic, Nashville, TN 37232

Open in the dashboard

General payments

$99,588

201 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Smita De of Nashville, TN is reported in the CMS Open Payments database as having received $99,588 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,173 69
2024 General $40,233 67
2023 General $24,256 44
2022 General $1,290 12
2021 General $509 7
2020 General $16 1
2019 General $111 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Smita De
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Smita De were reported at $33,173. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Smita De Urology median Middle half National median
2019 $111 $480 $147–$1,201 $163
2020 $16 $246 $87–$645 $114
2021 $509 $358 $111–$1,000 $132
2022 $1,290 $476 $143–$1,263 $149
2023 $24,256 $560 $168–$1,461 $160
2024 $40,233 $563 $170–$1,464 $164
2025 $33,173 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $88,614 135 payments
  2. KARL STORZ Endoscopy-America $8,162 13 payments
  3. Cook Medical LLC $887 22 payments
  4. Coloplast Corp $834 11 payments
  5. Richard Wolf Medical Instruments Corp. $371 5 payments
  6. C. R. Bard, Inc. & Subsidiaries $286 3 payments
  7. Calyxo, Inc. $206 3 payments
  8. Dornier MedTech America, Inc $124 1 payment
  9. PROCEPT BioRobotics Corporation $23 1 payment
  10. Laborie Medical Technologies Corp. $23 1 payment
  11. Other $59 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $64,930 24 payments
  2. Consulting Fee $14,893 11 payments
  3. Travel and Lodging $11,587 45 payments
  4. Food and Beverage $8,170 118 payments
  5. Education $8 3 payments
Products named General payments · program years 2019–2025
  1. Lumenis Pulse 120H $19,704 41 payments
  2. General - BPH $17,827 15 payments
  3. GreenLight XPS $11,527 18 payments
  4. n.a. $5,891 2 payments
  5. Moses 550 D\F\L $1,796 7 payments
  6. Flex-X $742 2 payments
  7. LITHO 150 $693 18 payments
  8. General - Therapies $378 4 payments
  9. Porges Coloplast $344 4 payments
  10. Coloplast TFL Drive $322 2 payments
  11. Other $1,961 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

435

Median for Urology: 1,053

Drug cost

$21,926

Median for Urology: $101,464

Branded share of claims

18.6%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 29 $16,485
Tamsulosin Hcl Generic 157 $1,801
Finasteride Generic 130 $1,369
Potassium Citrate Er Potassium Citrate Brand 16 $947
Alfuzosin Hcl Er Alfuzosin Hcl Brand 24 $623
Trospium Chloride Generic 18 $452
Cephalexin Generic 26 $155
Ciprofloxacin Hcl Generic 11 $37
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $37
Amoxicillin Generic 12 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$80,414

Medicare's payments for the services billed

Medicare patients

256

Average age 74

Services billed

846

44 women, 212 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 43%
Ischemic heart disease 35%
Diabetes 26%
Chronic kidney disease 26%
Cancer 23%
Atrial fibrillation 19%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record